13F Pro

SEC Form 4 reporting owner

Cook Jennifer E.

Cook Jennifer E. has filed 19 Form 4 transactions reported between June 3, 2026 and August 31, 2026, as Director of Jazz Pharmaceuticals plc, Director of BridgeBio Pharma, Inc. and Director of Denali Therapeutics Inc..

Name as filed: Cook Jennifer E.

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$11.8M
5 lines
Companies
3
with Form 4 filings
Latest transaction
Aug 31, 2026
transaction date

Roles and reported holdings

  • JAZZJazz Pharmaceuticals plc
    Aug 5, 2026 – Aug 31, 2026

    Director

    Held directly10,736 sh as of Aug 31, 2026 · Form 4
  • BBIOBridgeBio Pharma, Inc.
    Jun 15, 2026 – Jul 9, 2026

    Director

    Held directly120,805 sh as of Jul 9, 2026 · Form 4

    24 months: $11.8M sold

  • DNLIDenali Therapeutics Inc.
    Jun 3, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 19 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Aug 31, 2026JAZZDirectorShares withheld for tax or exercise priceCode F · direct1,692$408K@ $241.39Form 4
Aug 31, 2026JAZZDirectorShares withheld for tax or exercise priceCode F · direct14$3K@ $244.06Form 4
Aug 5, 2026JAZZDirectorGrant or awardCode A · direct1,605—Form 4
Jul 9, 2026BBIODirectorOpen-market saleCode S · direct36,167$3.0M@ $84.00Form 4
Jul 9, 2026BBIODirectorOption exerciseCode M · direct17,167$288K@ $16.75Form 4
Jul 9, 2026BBIODirectorOption exerciseCode M · direct112,422$3.3M@ $29.00Form 4
Jul 9, 2026BBIODirectorOption exerciseCode M · direct19,000$161K@ $8.45Form 4
Jun 24, 2026BBIODirectorOpen-market saleCode S · direct37,167$2.6M@ $70.00Form 4
Jun 24, 2026BBIODirectorOption exerciseCode M · direct17,167$288K@ $16.75Form 4
Jun 24, 2026BBIODirectorOption exerciseCode M · direct20,000$169K@ $8.45Form 4
Jun 23, 2026BBIODirectorOpen-market saleCode S · directAlso reported by Valantine Hannah2,196$151K@ $68.57Form 4
Jun 22, 2026BBIODirectorGrant or awardCode A · direct5,277—Form 4
Jun 22, 2026BBIODirectorGrant or awardCode A · direct3,990—Form 4
Jun 15, 2026BBIODirectorOpen-market saleCode S · direct1,503$101K@ $67.14Form 4
Jun 15, 2026BBIODirectorOpen-market saleCode S · direct88,737$5.9M@ $66.62Form 4
Jun 15, 2026BBIODirectorOption exerciseCode M · direct17,167$288K@ $16.75Form 4
Jun 15, 2026BBIODirectorOption exerciseCode M · direct65,921$557K@ $8.45Form 4
Jun 3, 2026DNLIDirectorGrant or awardCode A · direct19,226—Form 4
Jun 3, 2026DNLIDirectorGrant or awardCode A · direct6,408—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.